Literature DB >> 16023068

Neuro-ophthalmologic and electroretinographic findings in pantothenate kinase-associated neurodegeneration (formerly Hallervorden-Spatz syndrome).

Robert A Egan1, Richard G Weleber, Penelope Hogarth, Allison Gregory, Jason Coryell, Shawn K Westaway, Jane Gitschier, Soma Das, Susan J Hayflick.   

Abstract

PURPOSE: The onset of pantothenate kinase-associated neurodegeneration (PKAN) occurs in the first and second decade of life and a pigmentary retinal degeneration is a feature of the disorder. Since the neuro-ophthalmologic and electroretinographic (ERG) features have never been well delineated, we describe them in 16 patients with PKAN.
DESIGN: Observational case series.
METHODS: Sixteen patients with genetic and neuroimaging-confirmed PKAN were examined. Ten underwent neuro-ophthalmologic examination and all had ERGs.
RESULTS: Of the 10 who underwent neuro-ophthalmologic examination, all showed saccadic pursuits and eight showed hypometric or slowed vertical saccades. Seven of eight had inability to suppress the vestibulo-ocular reflex; two patients could not cooperate. Two had square wave jerks and four had poor convergence. Vertical optokinetic responses were abnormal in five, and two patients had blepharospasm. Eight patients had sectoral iris paralysis and partial loss of the pupillary ruff consistent with Adie's pupils in both eyes. Only four of 10 examined patients showed a pigmentary retinopathy, but 11 of 16 had abnormal ERGs ranging from mild cone abnormalities to severe rod-cone dysfunction. No patient had optic atrophy. The PANK2 mutations of all of the patients were heterogeneous.
CONCLUSIONS: Adie's-like pupils, abnormal vertical saccades, and saccadic pursuits were very common. These findings suggest that mid-brain degeneration occurs in PKAN more frequently than previously thought. ERG abnormalities were present in approximately 70% and no patient had optic atrophy. Although genotype-ocular phenotype correlations could not be established, allelic differences probably contributed to the variable clinical expression of retinopathy and other clinical characteristics in these patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16023068      PMCID: PMC2169522          DOI: 10.1016/j.ajo.2005.03.024

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  22 in total

1.  How broad is the phenotype of Hallervorden-Spatz disease?

Authors:  S J Hickman; N S Ward; R A Surtees; J M Stevens; S F Farmer
Journal:  Acta Neurol Scand       Date:  2001-03       Impact factor: 3.209

2.  A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome.

Authors:  B Zhou; S K Westaway; B Levinson; M A Johnson; J Gitschier; S J Hayflick
Journal:  Nat Genet       Date:  2001-08       Impact factor: 38.330

Review 3.  Optic atrophy as the first symptom in Hallervorden-Spatz syndrome.

Authors:  P A Battistella; E Midena; A Suppiej; C Carollo
Journal:  Childs Nerv Syst       Date:  1998-03       Impact factor: 1.475

4.  Standard for clinical electroretinography (1994 update).

Authors:  M F Marmor; E Zrenner
Journal:  Doc Ophthalmol       Date:  1995       Impact factor: 2.379

5.  Hallervorden-Spatz disease with bilateral involvement of globus pallidus and substantia nigra: MR demonstration.

Authors:  L Porter-Grenn; R Silbergleit; B A Mehta
Journal:  J Comput Assist Tomogr       Date:  1993 Nov-Dec       Impact factor: 1.826

6.  Early clinical and imaging (high-field MRI) diagnosis of Hallervorden-Spatz disease.

Authors:  M Feliciani; P Curatolo
Journal:  Neuroradiology       Date:  1994-04       Impact factor: 2.804

7.  Clinicopathologic correlation and pathogenesis of ocular and central nervous system manifestations in Hallervorden-Spatz syndrome.

Authors:  R C Tripathi; B J Tripathi; S C Bauserman; J K Park
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

8.  Alpha-synuclein accumulation in a case of neurodegeneration with brain iron accumulation type 1 (NBIA-1, formerly Hallervorden-Spatz syndrome) with widespread cortical and brainstem-type Lewy bodies.

Authors:  M Neumann; S Adler; O Schlüter; E Kremmer; R Benecke; H A Kretzschmar
Journal:  Acta Neuropathol       Date:  2000-11       Impact factor: 17.088

9.  Posterior subcapsular cataract in Degos disease.

Authors:  R Egan; S Lessell
Journal:  Am J Ophthalmol       Date:  2000-06       Impact factor: 5.258

Review 10.  The dystrophic retina in multisystem disorders: the electroretinogram in neuronal ceroid lipofuscinoses.

Authors:  R G Weleber
Journal:  Eye (Lond)       Date:  1998       Impact factor: 3.775

View more
  23 in total

Review 1.  Genetics of neurodegeneration with brain iron accumulation.

Authors:  Allison Gregory; Susan J Hayflick
Journal:  Curr Neurol Neurosci Rep       Date:  2011-06       Impact factor: 5.081

Review 2.  Pantothenate kinase-associated neurodegeneration (PKAN) and PLA2G6-associated neurodegeneration (PLAN): review of two major neurodegeneration with brain iron accumulation (NBIA) phenotypes.

Authors:  Manju A Kurian; Susan J Hayflick
Journal:  Int Rev Neurobiol       Date:  2013       Impact factor: 3.230

Review 3.  Neurodegeneration with brain iron accumulation.

Authors:  Allison Gregory; Susan J Hayflick
Journal:  Folia Neuropathol       Date:  2005       Impact factor: 2.038

Review 4.  [Anesthesia in patients with NBIA : Neurodegeneration with brain iron accumulation].

Authors:  T Warnecke; J Schmitz; S Kerkhoff; J Hinkelbein
Journal:  Anaesthesist       Date:  2018-11       Impact factor: 1.041

Review 5.  Vertical supranuclear gaze palsy in Niemann-Pick type C disease.

Authors:  Ettore Salsano; Chizoba Umeh; Alessandra Rufa; Davide Pareyson; David S Zee
Journal:  Neurol Sci       Date:  2012-07-19       Impact factor: 3.307

6.  Microarray analysis of murine retinal light damage reveals changes in iron regulatory, complement, and antioxidant genes in the neurosensory retina and isolated RPE.

Authors:  Majda Hadziahmetovic; Usha Kumar; Ying Song; Steven Grieco; Delu Song; Yafeng Li; John W Tobias; Joshua L Dunaief
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-08-07       Impact factor: 4.799

7.  Neurodegeneration with brain iron accumulation: A case report.

Authors:  Daniel Nassif; João Santos Pereira; Mariana Spitz; Cláudia Capitão; Alessandra Faria
Journal:  Dement Neuropsychol       Date:  2016 Apr-Jun

Review 8.  Clinical and genetic delineation of neurodegeneration with brain iron accumulation.

Authors:  A Gregory; B J Polster; S J Hayflick
Journal:  J Med Genet       Date:  2008-11-03       Impact factor: 6.318

Review 9.  Neurodegeneration with Brain Iron Accumulation.

Authors:  Susanne A Schneider
Journal:  Curr Neurol Neurosci Rep       Date:  2016-01       Impact factor: 5.081

10.  β-Propeller protein-associated neurodegeneration: a new X-linked dominant disorder with brain iron accumulation.

Authors:  Susan J Hayflick; Michael C Kruer; Allison Gregory; Tobias B Haack; Manju A Kurian; Henry H Houlden; James Anderson; Nathalie Boddaert; Lynn Sanford; Sami I Harik; Vasuki H Dandu; Nardo Nardocci; Giovanna Zorzi; Todd Dunaway; Mark Tarnopolsky; Steven Skinner; Kenton R Holden; Steven Frucht; Era Hanspal; Connie Schrander-Stumpel; Cyril Mignot; Delphine Héron; Dawn E Saunders; Margaret Kaminska; Jean-Pierre Lin; Karine Lascelles; Stephan M Cuno; Esther Meyer; Barbara Garavaglia; Kailash Bhatia; Rajith de Silva; Sarah Crisp; Peter Lunt; Martyn Carey; John Hardy; Thomas Meitinger; Holger Prokisch; Penelope Hogarth
Journal:  Brain       Date:  2013-05-17       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.